Nothing Special   »   [go: up one dir, main page]

GB9621757D0 - Phenyl-substituted bicyclic heterocyclyl derivatives and their use - Google Patents

Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Info

Publication number
GB9621757D0
GB9621757D0 GBGB9621757.5A GB9621757A GB9621757D0 GB 9621757 D0 GB9621757 D0 GB 9621757D0 GB 9621757 A GB9621757 A GB 9621757A GB 9621757 D0 GB9621757 D0 GB 9621757D0
Authority
GB
United Kingdom
Prior art keywords
phenyl
bicyclic heterocyclyl
substituted bicyclic
heterocyclyl derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9621757.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to GBGB9621757.5A priority Critical patent/GB9621757D0/en
Publication of GB9621757D0 publication Critical patent/GB9621757D0/en
Priority to AU49479/97A priority patent/AU4947997A/en
Priority to PCT/EP1997/005697 priority patent/WO1998017662A1/en
Pending legal-status Critical Current

Links

GBGB9621757.5A 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use Pending GB9621757D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9621757.5A GB9621757D0 (en) 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use
AU49479/97A AU4947997A (en) 1996-10-18 1997-10-16 Phenyl-substituted bicyclic heterocyclyl derivatives and their use
PCT/EP1997/005697 WO1998017662A1 (en) 1996-10-18 1997-10-16 Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9621757.5A GB9621757D0 (en) 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Publications (1)

Publication Number Publication Date
GB9621757D0 true GB9621757D0 (en) 1996-12-11

Family

ID=10801645

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9621757.5A Pending GB9621757D0 (en) 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Country Status (3)

Country Link
AU (1) AU4947997A (en)
GB (1) GB9621757D0 (en)
WO (1) WO1998017662A1 (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003527B1 (en) 1997-10-27 2003-06-26 Агурон Фармасьютикалз, Инк. Substituted 4-aminothiazoles as inhibitors of cyclin-dependent kinases
FR2781154B1 (en) * 1998-07-15 2001-09-07 Lafon Labor THERAPEUTIC COMPOSITION BASED ON ISOFLAVONOIDS FOR USE IN THE TREATMENT OF TUMORS WITH CYTOTOXIC AGENTS
FR2797444B1 (en) * 1999-08-13 2003-02-07 Lafon Labor PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
WO2001083469A1 (en) * 2000-05-03 2001-11-08 Lg Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
KR100399364B1 (en) * 2000-09-18 2003-09-26 주식회사 엘지생명과학 3-Hydroxy-6-aminochromene-4-on derivatives useful as cyclin dependendent kinase inhibitors
MXPA03001189A (en) 2000-08-09 2004-05-14 Agouron Pharma Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases.
DE60110802T2 (en) 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego HETEROCYCLIC HYDROXIMINO FLUORENE AND ITS USE IN THE INHIBITION OF PROTEIN KINASES
FR2813791B1 (en) * 2000-09-14 2004-03-12 Lafon Labor USE OF 2- AND 4-QUINOLONES TO INHIBIT INTIMAL NEO-PROLIFERATION
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2003265737B2 (en) * 2002-10-02 2008-10-16 Novogen Research Pty Ltd Combination chemotherapy compositions and methods
CN100378105C (en) * 2003-01-31 2008-04-02 中国人民解放军南京军区联勤部军事医学研究所 Pyran isoflavone molluscacide synthesizing method and formulation
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
MX2007003216A (en) 2004-09-21 2008-03-10 Novogen Res Pty Ltd Substituted chroman derivatives, medicaments and use in therapy.
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006099193A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
AU2007283570A1 (en) * 2006-08-10 2008-02-14 Ferrer Internacional S.A. 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
TWI472525B (en) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
CA2745015A1 (en) * 2008-12-05 2010-06-10 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical agent comprising quinolone compound
JP2012518657A (en) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー Combined anticancer treatment
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
EP2510110A1 (en) 2009-11-13 2012-10-17 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012061409A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
JP2014519813A (en) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
CA2849120A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
CN105017145B (en) * 2012-12-12 2017-12-05 王子厚 7-chloro-4-oxo-quinoline derivative with antitumor activity
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
KR20170095893A (en) 2014-12-24 2017-08-23 제넨테크, 인크. Therapeutic, diagnostic, and prognostic methods for cancer of the bladder
MX2017010002A (en) 2015-02-02 2018-02-09 Mei Pharma Inc Combination therapies.
NZ754994A (en) 2016-12-22 2022-12-23 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
CA3108484A1 (en) * 2017-08-04 2019-02-07 Anthony Stewart Campbell Inhibitors of microbially induced amyloid
AR112797A1 (en) 2017-09-08 2019-12-11 Amgen Inc KRAS G12C INHIBITORS AND METHODS OF USING THEM
JP7266043B2 (en) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド KRas G12C inhibitors and methods of using them
MX2020011582A (en) 2018-05-04 2020-11-24 Amgen Inc Kras g12c inhibitors and methods of using the same.
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012731A (en) 2018-06-01 2021-02-22 Amgen Inc Kras g12c inhibitors and methods of using the same.
MX2020012204A (en) 2018-06-11 2021-03-31 Amgen Inc Kras g12c inhibitors for treating cancer.
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
CN113194954A (en) 2018-10-04 2021-07-30 国家医疗保健研究所 EGFR inhibitors for the treatment of keratoderma
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
UY38526A (en) 2018-12-20 2020-06-30 Amgen Inc KIF18A INHIBITORS
US20220056015A1 (en) 2018-12-20 2022-02-24 Amgen Inc. Kif18a inhibitors
MX2021007157A (en) 2018-12-20 2021-08-16 Amgen Inc Heteroaryl amides useful as kif18a inhibitors.
AU2019403488A1 (en) 2018-12-20 2021-06-24 Amgen Inc. KIF18A inhibitors
CN113727758A (en) 2019-03-01 2021-11-30 锐新医药公司 Bicyclic heterocyclic compounds and use thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CA3225293A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
EP4007752A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
JP2022542319A (en) 2019-08-02 2022-09-30 アムジエン・インコーポレーテツド KIF18A inhibitor
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
EP4055028A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
TW202132315A (en) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras inhibitors
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
JP2023500328A (en) 2019-11-08 2023-01-05 レボリューション メディシンズ インコーポレイテッド Bicyclic heteroaryl compound and use thereof
BR112022009390A2 (en) 2019-11-14 2022-08-09 Amgen Inc IMPROVED SYNTHESIS OF KRAS INHIBITOR COMPOUND G12C
EP4058432A1 (en) 2019-11-14 2022-09-21 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
JP2023509701A (en) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド SHP2 inhibitor dosing and methods of treating cancer
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
CN118852330A (en) 2021-05-05 2024-10-29 锐新医药公司 RAS inhibitors for the treatment of cancer
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE666541A (en) * 1964-07-08
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
FR2693724B1 (en) * 1992-07-17 1994-10-07 Lipha Use of benzopyran or benzothiopyran compounds for the induction of the expression of genes for the nodulation of bacteria of the genus Rhizobium associated with legumes.
US5741476A (en) * 1992-12-21 1998-04-21 Mallinckrodt Medical, Inc. Polyhydric phenol compounds
WO1996035683A1 (en) * 1995-05-09 1996-11-14 Nippon Kayaku Kabushiki Kaisha Novel physiologically active na23063 analogues, process for producing the same and use of the same

Also Published As

Publication number Publication date
AU4947997A (en) 1998-05-15
WO1998017662A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
GB9621757D0 (en) Phenyl-substituted bicyclic heterocyclyl derivatives and their use
GB2324672B (en) Vision system and proximity detector
ZA9710339B (en) Xanthines and their therapeutic use
HRP970680B1 (en) New ketobenzamides and their use
IL135375A0 (en) Dihydro and tetrahydroisoquinoline derivatives
HK1007865A1 (en) Sulphonamides and their use
IL120124A0 (en) Heteroaryl-oxazolidinones their preparation and use
HK1005801A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
GB9620390D0 (en) Substances and their uses
HUP9902463A3 (en) Fixture and prosthesis including the same
EP1021185A4 (en) Didhydropyrimidines and uses thereof
ZA979420B (en) Alpha-branched fluoroalkylcarbonyl fluorides and their derivatives
EP0894807A4 (en) GPIb-LIPID COMPLEX AND USES THEREOF
HRP970225A2 (en) Benzofuryl derivatives and their use
ZA975591B (en) New amidino derivatives and their use as thrombininhibitors
GB2304309B (en) Laminate and use thereof
AU1886197A (en) Quinolones and their therapeutic use
IL126476A0 (en) Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents
HUP9700446A3 (en) Oilsuspension-concentrate and using thereof
GB9617322D0 (en) Triazine derivatives and their use
ZA978876B (en) Oxazolone derivatives and their use
PL331523A1 (en) Azolotrizines and azolopyrimidines
AU3116697A (en) Human interleukin-1j and antagonists thereof
IL123535A0 (en) Benzoxazindione derivatives and their use
EP0744125A3 (en) Iodo-complex and its use